Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a consumer health company worldwide. Valued at $39.8 billion by market cap, the company offers a consumer health portfolio in self-care, skin health & beauty, and essential health products. The world’s largest pure-play consumer health company is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Thursday, Feb. 6.
Ahead of the event, analysts expect KVUE to report a profit of $0.25 per share on a diluted basis, down 19.4% from $0.31 per share in the year-ago quarter. The company beat the consensus estimate in each of the last four quarters.
For the full year, analysts expect KVUE to report EPS of $1.14, down 11.6% from $1.29 in fiscal 2023. However, its EPS is expected to rise 4.4% year over year to $1.19 in fiscal 2025.
KVUE stock has underperformed the S&P 500’s ($SPX) 25.8% gains over the past 52 weeks, with shares down marginally during this period. Similarly, it underperformed the Consumer Staples Select Sector SPDR Fund’s (XLP) 6.9% gains over the same time frame.
On Nov. 7, KVUE shares closed up more than 2% after reporting its Q3 results. Its adjusted EPS of $0.28 surpassed Wall Street expectations of $0.27. The company’s revenue was $3.9 billion, falling short of Wall Street forecasts of $3.92 billion. KVUE expects full-year adjusted EPS to be between $1.10 and $1.20.
Analysts’ consensus opinion on KVUE stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 15 analysts covering the stock, six advise a “Strong Buy” rating, eight give a “Hold,” and one recommends a “Strong Sell.” KVUE’s average analyst price target is $23.64, indicating a potential upside of 13.9% from the current levels.
